KR20190066637A - Composition for preventing and treating a cancer comprising Silene repens Patrin - Google Patents
Composition for preventing and treating a cancer comprising Silene repens Patrin Download PDFInfo
- Publication number
- KR20190066637A KR20190066637A KR1020170147826A KR20170147826A KR20190066637A KR 20190066637 A KR20190066637 A KR 20190066637A KR 1020170147826 A KR1020170147826 A KR 1020170147826A KR 20170147826 A KR20170147826 A KR 20170147826A KR 20190066637 A KR20190066637 A KR 20190066637A
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- extract
- carcinoma
- patrin
- silene
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 28
- 201000011510 cancer Diseases 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims description 23
- 241000606656 Silene repens Species 0.000 title claims description 15
- 239000000284 extract Substances 0.000 claims abstract description 72
- 210000004027 cell Anatomy 0.000 claims abstract description 44
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims abstract description 26
- 230000001093 anti-cancer Effects 0.000 claims abstract description 13
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 36
- 208000034578 Multiple myelomas Diseases 0.000 claims description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 230000036541 health Effects 0.000 claims description 17
- 235000013376 functional food Nutrition 0.000 claims description 13
- 235000013402 health food Nutrition 0.000 claims description 13
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 11
- 230000006907 apoptotic process Effects 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 206010014733 Endometrial cancer Diseases 0.000 claims description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010047741 Vulval cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000004916 vulva carcinoma Diseases 0.000 claims description 3
- 208000013013 vulvar carcinoma Diseases 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 2
- 201000005746 Pituitary adenoma Diseases 0.000 claims description 2
- 206010061538 Pituitary tumour benign Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000003911 head and neck carcinoma Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 208000021310 pituitary gland adenoma Diseases 0.000 claims description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 206010062261 spinal cord neoplasm Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 208000023747 urothelial carcinoma Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 102100029145 DNA damage-inducible transcript 3 protein Human genes 0.000 abstract description 11
- 230000014509 gene expression Effects 0.000 abstract description 11
- 101710156077 DNA damage-inducible transcript 3 protein Proteins 0.000 abstract description 10
- 239000001301 oxygen Substances 0.000 abstract description 10
- 229910052760 oxygen Inorganic materials 0.000 abstract description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 9
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 230000030833 cell death Effects 0.000 abstract description 4
- 230000001939 inductive effect Effects 0.000 abstract description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 22
- 230000001965 increasing effect Effects 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 229960005070 ascorbic acid Drugs 0.000 description 11
- 235000010323 ascorbic acid Nutrition 0.000 description 11
- 239000011668 ascorbic acid Substances 0.000 description 11
- 230000035882 stress Effects 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 4
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 4
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 4
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 210000004180 plasmocyte Anatomy 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- -1 olive oil Chemical compound 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000004906 unfolded protein response Effects 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710151717 Stress-related protein Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 238000009009 Protein Assay Kit II Methods 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241001335355 Silene firma Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108010057666 Transcription Factor CHOP Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000011866 pituitary adenocarcinoma Diseases 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 108020005087 unfolded proteins Proteins 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 왕불류행 추출물을 포함하는 암의 예방 및 치료용 조성물에 관한 것이다.The present invention relates to a composition for the prevention and treatment of cancer, including a long-acting extract.
2016년에 발표된 중앙암등록본부 자료에 의하면 2014년에 우리나라에서는 217,057건의 암이 발생했는데, 그 중 다발성골수종(C90)은 1,396건으로 전체 암 발생의 0.6%를 차지 하는 질병으로써 발병시 완치가 어려운 질병 중 하나이다. According to data released by the Central Cancer Registry in 2016, 217,057 cancers have occurred in Korea in 2014, among which 1,396 cases of multiple myeloma (C90) account for 0.6% of all cancers. It is one of the diseases.
다발성 골수종은 백혈병, 림프종과 함께 대표적인 혈액종양으로 B림프구의 성숙형태인 형질세포가 증식하는 혈액암이다. 평균 65세 이상의 고령에서 발병하며, 비교적 동양인에서는 낮은 발병율을 보이며, 1980년대 우리나라 발병율은 연간 100명이내로 매우 낮았다. 그러나 급속한 산업화에 따른 공해, 환경호르몬에 노출증가, 고령화로 인해 다발성 골수종 환자는 지속적으로 증가하고 있다. 지난 20년간 다른 암종의 발생률은 5배의 증가에 머물렀으나, 다발성 골수종의 경우, 약 30배 이상의 발생 증가를 보이고 있다. Multiple myeloma is a typical hematologic tumor with leukemia and lymphoma. It is a hematologic malignancy in which plasma cells, a mature form of B lymphocyte, proliferate. The average incidence is 65 years or older, relatively low in Asians, and the incidence rate in Korea is very low in the 1980s. However, due to rapid industrialization, increased exposure to environmental hormones, and aging, the number of patients with multiple myeloma continues to increase. Over the past two decades, the incidence of other carcinomas has increased fivefold, but the incidence of multiple myeloma has increased by more than 30-fold.
형질세포는 B림프구가 항원에 자극을 받아 최종적으로 분화되는 세포로 혈액이나 조직 내에 존재하며, 체내에 침입한 바이러스나 세균 등에 대항해 싸우는 단백질(항체,면역글로불린)을 생산, 저장, 분비하는데 혈액속의 형질세포는 B세포가 외부에서 들어온 침입자(항원)와 싸우기 위해 최종적으로 분화된 세포로써 이 형질세포와 골수에서는 각종 싸이토카인이라는 단백을 분비해 우리 몸에 필요한 항체를 만들게 되는데, 증상으로는 뼈의 용해성 병변, 신부전, 빈혈, 반복되는 감염 등으로 인한 골통증, 어지럼증 등의 여러 가지 임상증상을 나타낸다. 그러나 임상증상이 나타나기 전에 보통 일정기간의 무증상 기간이 선행되며 다발성골수종 환자의 20%는 증상 없이 우연히 발견되기도 한다.Plasma cells are cells in which B lymphocytes are stimulated by antigen and eventually differentiate. They are present in blood or tissues. They produce, store and secrete proteins (antibodies, immunoglobulins) that fight against viruses and bacteria that invade the body. Plasma cells are cells finally differentiated by B cells to fight intruders (antigens) from the outside. In these plasma cells and bone marrow, various proteins called cytokines are secreted to make antibodies for the body. Symptoms include bone solubility Lesions, renal failure, anemia, bone pain due to repeated infections, and dizziness. However, asymptomatic period precedes a certain period before clinical symptoms appear, and 20% of multiple myeloma patients are found incidentally without symptoms.
현재 시행되고 있는 치료법으로는 항암화학요법, 자가조혈모세포이식, 동종조혈모세포이식, 방사선치료 등이 있으나 치료과정에서 정상 세포들이 손상되어 여러 가지 합병증을 초래하기도 한다. 이에 우리는 부작용을 최소화 하고, 상승효과를 기대해 볼수 있는 천연 한방 재료를 이용하여 다발성 골수종 치료제를 개발 하고자 본 연구를 수행하였다. Currently, therapies include chemotherapy, autologous stem cell transplantation, allogeneic stem cell transplantation, and radiation therapy. We have conducted this study to develop a therapeutic agent for multiple myeloma using natural oriental herbal medicine which minimizes side effects and anticipates synergistic effects.
왕불류행은 패랭이꽃과 식물인 장구채 Melandrium firmum Rohrb.의 전초를 말린 것으로, 여름철 씨가 익기 전에 전초를 베어 햇볕에서 말린 것이다. 맛은 쓰고 달며 성질은 평하여 위경(胃經)에 작용한다고 알려져 있다. 왕불류행의 종자는 여러 종류의 사포닌을 함유하고 있으며, 전초에는 플라보노이드 성분이 다량 함유되어있어 혈액 순환을 촉진시켜 어혈을 풀어주고 월경을 고르게 하며 젖이 잘 나오게 한다. 또한 풍사(風邪)를 없애고 부기를 가라앉히며 출혈을 멎게 한다. 또한 약리 실험에서 면역 기능을 높이는 작용이 밝혀졌다. 또한 자궁근육을 흥분시키며, 폐암과 복수암 억제 효과가 있다고 보고된다. 그러나 다발성 골수암에는 아직 연구 보고가 된 바는 없다. 이에 우리는 다발성 골수암세포주에서 항암 효과를 알아보고자 연구를 수행하였다.Wangwolryu is the dried outpast of Melandrium firmum Rohrb., Which is dried out in the sun before the summer seeds ripen. It is known that it tastes sweet, it has a property of nature and acts on the stomach. The seeds of Wangwollu are composed of various kinds of saponin, and they contain a large amount of flavonoids in the outpouring, thereby promoting blood circulation, releasing the eosinophils, making the menstrual flow, and making the milk come out well. It also removes cold sores, calms the swelling and stops the bleeding. In addition, pharmacological experiments have been shown to enhance the immune function. It also stimulates the uterine muscle, and is reported to have lung cancer and multiple cancer inhibitory effects. However, there has been no report on multiple myeloma. Therefore, we investigated the anticancer effect of multiple myeloma cell lines.
생체의 모든 세포에 존재하는 소포체(Endoplasmic reticulum, ER)는 세포에서 단백질과 콜레스테롤 생산에 관여하는 소기관으로, 세포에서 단백질이 필요한 부위에 단백질을 전달하는 역할을 수행한다. 소포체(ER)에서 단백질들은 번역 후 수식(post-translational modification)과정을 거치게 되며 modification과 folding이 제대로 이루어져야만 이 곳을 통과시킨다. 그러므로 소포체는 분비 또는 막 단백질의 품질관리에 매우 중요한 기관이다. The endoplasmic reticulum (ER), which is present in all cells of living organisms, is an organelle involved in the production of proteins and cholesterol in cells. In the ER, proteins are post-translationally modified, and only through modification and folding they pass through. Therefore, the endoplasmic reticulum is an important organ for quality control of secretion or membrane protein.
ER에서 unfolded protein이 축적되어 나타나는 반응이 unfolded protein response (UPR)인데 이러한 반응이 일어나도록 하는 자극들을 ER stress라고 부른다. 실험적으로는 ER은 산화적환경을 유지하고 있기 때문에 세포에 DTT나 beta-mercaptoethanol과 같은 환원제를 처리하면 UPR가 일어나게 된다. ER stress는 소포체가 처리할 수 있는 능력 이상의 단백질이 소포체 내로 유입되거나 소포체 내 칼슘이 고갈돼 소포체 기능에 장애가 발생하는 상태를 일컫는데, 이는 암의 발달과 유지에 영향을 주기 때문에 중요한 암 치료 타깃으로 생각되고 있다. ER stress가 심해지면 손상된 세포를 제거하기위해 세포사멸 (apoptosis)을 유도한게 되는데 이 과정에서 CHOP/GADD153이 중요한 매계체로 작용한다. 이러한 ER stress의해 유도된 세포사멸 경호 활성은 허혈성 혈관질환에서 활성산소(ROS)와도 연관이 있다고 보고되었다.The unfolded protein response (UPR) is the accumulation of unfolded protein in ER, and the stimuli that cause this reaction are called ER stress. Experimentally, the ER maintains an oxidative environment, so UPR occurs when cells are treated with a reducing agent such as DTT or beta-mercaptoethanol. ER stress refers to a state in which proteins above the ability of the endoplasmic reticulum to treat are introduced into the endoplasmic reticulum or depleted of calcium in the endoplasmic reticulum, resulting in a failure of the endoplasmic reticulum. This is an important cancer treatment target because it affects the development and maintenance of cancer I think. When ER stress is increased, it induces apoptosis in order to remove damaged cells. In this process, CHOP / GADD153 acts as an important all system. These ER stress-induced apoptosis-protective activities were also reported to be associated with reactive oxygen species (ROS) in ischemic vascular disease.
대부분의 생명체는 공기 중의 산소를 호흡하여 산화시켜 얻어지는 에너지를 이용하여 생명을 유지하는데, 이런 산소가 필요한 대사과정에서 불가피하게 세포를 파괴시키는 독성물질들이 부산물로 만들어지는데 이것을 활성산소((reactive oxygen species, ROS)라고 한다. Most living organisms use life-sustaining energy to breathe oxygen in the air. In the metabolic processes that require this oxygen, the toxins that inevitably destroy the cells become byproducts, which are called reactive oxygen species , ROS).
이런 ROS는 정상적인 세포내 활성작용 과정에서 생성되며 세포분화, 유전자의 발현, 사이토카인에 분비 등을 포함한 여러 생물학적 과정에 연관되어 있다. 산화적스트레스는 활성산소의 생성과 이를 제거하는 항산화 반응간의 불균형으로 인해 세포내 활성산소가 증가하여 DNA나 단백질, 지질(lipid)과 반응하여 손상시키는 현상으로 이러한 ROS의 항상성을 유지하는 것은 정상세포 뿐만 아니라 암세포성장과 생존에 매우 중요하다.These ROS are produced during normal intracellular activity and are involved in various biological processes including cell differentiation, gene expression, and secretion into cytokines. Oxidative stress is a phenomenon that increases the active oxygen in the cell due to the imbalance between the production of active oxygen and the antioxidative reaction that removes it, and it reacts with DNA, protein, and lipid to damage this homeostasis. It is also important for cancer cell growth and survival.
이에, 본 발명자는 왕불류행 추출물이 cleaved-PARP 및 CHOP(C/EBP homologous protein)의 발현량을 증가시켜 세포 내의 활성 산소의 생성량을 증가시키고, 이에 따라 소포체(endoplasmic reticulum, ER) 스트레스에 의한 세포사멸을 유도함으로써 다발성 골수암에 대하여 항암 효과가 우수함을 알아내고 본 발명을 완성하였다.Accordingly, the present inventors have found that the extract of Wangwol-In increases the amount of cleaved-PARP and CHOP (C / EBP homologous protein) expression, thereby increasing the amount of active oxygen in the cell, and thus the endoplasmic reticulum The present invention has been completed based on the finding that the anticancer effect against multiple myeloma is excellent.
본 발명은 왕불류행(Silene repens Patrin) 추출물을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물을 제공하는 것이다.The present invention provides a pharmaceutical composition for preventing or treating cancer comprising an extract of Silene repens Patrin as an active ingredient.
본 발명의 다른 목적은 왕불류행(Silene repens Patrin) 추출물을 포함하는 항암보조제 조성물을 제공하는 것이다.Another object of the present invention is to provide an anticancer adjuvant composition comprising a Silene repens Patrin extract.
본 발명의 또 다른 목적은 왕불류행(Silene repens Patrin) 추출물을 포함하는 암의 예방 또는 개선용 건강기능식품 조성물을 제공하는 것이다.It is still another object of the present invention to provide a health functional food composition for preventing or ameliorating a cancer including a Silene repens Patrin extract.
본 발명의 다른 목적은 왕불류행(Silene repens Patrin) 추출물을 포함하는 암의 예방 또는 개선용 건강식품 조성물을 제공하는 것이다.It is another object of the present invention to provide a health food composition for preventing or ameliorating cancer comprising a Silene repens Patrin extract.
상기 목적을 달성하기 위하여,In order to achieve the above object,
본 발명은 왕불류행(Silene repens Patrin) 추출물을 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물을 제공한다.The present invention provides a pharmaceutical composition for preventing or treating cancer comprising an extract of Silene repens Patrin as an active ingredient.
또한, 본 발명은 왕불류행(Silene repens Patrin) 추출물을 포함하는 항암보조제 조성물을 제공한다.The present invention also provides an anticancer adjuvant composition comprising a Silene repens Patrin extract.
나아가, 본 발명은 왕불류행(Silene repens Patrin) 추출물을 포함하는 암의 예방 또는 개선용 건강기능식품 조성물을 제공한다.Further, the present invention provides a health functional food composition for preventing or ameliorating a cancer including a Silene repens Patrin extract.
또한, 본 발명은 왕불류행(Silene repens Patrin) 추출물을 포함하는 암의 예방 또는 개선용 건강식품 조성물을 제공한다.In addition, the present invention provides a health food composition for preventing or ameliorating cancer comprising a Silene repens Patrin extract.
본 발명에 따르면, 왕불류행 추출물은 cleaved-PARP 및 CHOP(C/EBP homologous protein)의 발현량을 증가시켜 세포 내의 활성 산소의 생성량을 증가시키고, 이에 따라 소포체(endoplasmic reticulum, ER) 스트레스에 의한 세포사멸이 유도됨으로써, 암의 예방 또는 치료에 유용하게 사용될 수 있다. According to the present invention, the extract of Wangboryu increases the amount of cleaved-PARP and CHOP (C / EBP homologous protein) expression, thereby increasing the amount of active oxygen in the cell, and thus, the endoplasmic reticulum It can be usefully used for prevention or treatment of cancer.
도 1a는 왕불류행 추출물 처리에 의한 다발성 골수종 세포주 U937의 세포 생존율을 확인한 결과이다.
도 1b는 왕불류행 추출물 처리에 의한 다발성 골수종 세포주 U266의 세포 생존율을 확인한 결과이다.
도 2a는 왕불류행 추출물 처리에 의한 다발성 골수종 세포주 U937의 세포사멸 관련 단백질과 ER스트레스 유발 관련 단백질의 발현 정도를 확인한 결과이다.
도 2b는 왕불류행 추출물 처리에 의한 다발성 골수종 세포주 U266의 세포사멸 관련 단백질과 ER스트레스 유발 관련 단백질의 발현 정도를 확인한 결과이다.
도 3a는 왕불류행 추출물 처리에 의한 다발성 골수종 세포주 U937의 활성산소 생성과 세포 독성 사이 상관관계를 확인한 결과이다.
도 3b는 왕불류행 추출물 처리에 의한 다발성 골수종 세포주 U266의 활성산소 생성과 세포 독성 사이 상관관계를 확인한 결과이다.FIG. 1A shows the cell survival rate of the multiple myeloma cell line U937 by the treatment with the ascorbic acid extract.
FIG. 1B shows the results of confirming the cell survival rate of the multiple myeloma cell line U266 by the treatment with the ascorbic acid extract.
FIG. 2A shows the results of confirming the expression levels of the apoptosis-related protein and the ER stress-related protein of the multiple myeloma cell line U937 by the treatment with the ascorbic acid extract.
FIG. 2b shows the results of confirming the expression level of the apoptosis-related protein and the ER stress-inducing protein of the multiple myeloma cell line U266 by the treatment with the ascorbic acid extract.
FIG. 3A shows the result of confirming the correlation between the production of active oxygen and the cytotoxicity of the multiple myeloma cell line U937 by the treatment with the ascorbic acid extract.
FIG. 3B shows the result of confirming the correlation between active oxygen production and cytotoxicity of the multiple myeloma cell line U266 by the treatment with the ascorbic acid extract.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
암의 예방 또는 치료용 약학적 조성물Pharmaceutical composition for preventing or treating cancer
본 발명은 왕불류행 (Silene repens Patrin) 추출물을 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물을 제공한다.The present invention provides a pharmaceutical composition for preventing or treating cancer comprising an extract of Silene repens Patrin as an active ingredient.
본 발명에서 용어, "추출물(extract)"은 생약을 적절한 침출액으로 짜내고 침출액을 증발시켜 농축한 제제를 의미하는 것으로, 이에 제한되지는 않으나, 추출처리에 의해 얻어지는 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 얻어지는 건조물, 이들의 조정제물 또는 정제물일 수 있다. 상기 왕불류행 추출물은 통상의 기술 분야에 공지된 일반적인 추출방법, 분리 및 정제방법을 이용하여 제조할 수 있다. 상기 추출방법으로는, 이에 제한되지는 않으나, 바람직하게 열탕 추출, 열수 추출, 냉침 추출, 환류 냉각 추출 또는 초음파 추출 등의 방법을 사용할 수 있다.The term "extract" in the present invention means a preparation which is prepared by squeezing a herbal medicine with an appropriate extract solution and evaporating the extract solution. The extract solution obtained by the extraction treatment, the diluent or concentrate of the extract, Or a dried product obtained by drying the above, a controlled preparation thereof or a purified product thereof. The long-acting extract can be prepared by a general extraction method, separation and purification methods well known in the art. The extraction method may be, but not limited to, hot water extraction, hot water extraction, cold extraction, reflux cooling extraction, or ultrasonic extraction.
본 발명에서, 추출용매는 물, 유기용매 또는 이들의 혼합용매 등을 사용할 수 있으며, 상기 유기용매는 탄소수 1 내지 4의 알코올이나, 에틸아세테이트 또는 아세톤 등의 극성용매, 헥산 또는 디크로로메탄의 비극성용매 또는 이들의 혼합용매를 사용할 수 있다. 또한, 바람직하게는 물, 탄소수 1 내지 4의 알코올 또는 이들의 혼합용매를 사용할 수 있으며, 보다 바람직하게는 에탄올을 사용할 수 있다. In the present invention, the extraction solvent may be water, an organic solvent or a mixed solvent thereof. The organic solvent may be an alcohol having 1 to 4 carbon atoms, a polar solvent such as ethyl acetate or acetone, a hexane or a dichloromethane A nonpolar solvent or a mixed solvent thereof may be used. Further, water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof may be preferably used, and more preferably ethanol can be used.
본 발명의 일실시예에 있어서, 용매로서 100% 에탄올을 이용하여 추출한 뒤 감압 농축한 왕불류행 추출물을 제조하였다.In one embodiment of the present invention, the extract was extracted with 100% ethanol as a solvent, and then concentrated under reduced pressure to prepare a long-acting extract.
본 발명에서, 상기 암은 다발성 골수종, 대장암, 유방암, 자궁암, 자궁경부암, 난소암, 전립선암, 뇌종양, 두경부암종, 흑색종, 골수종, 백혈병, 림프종, 위암, 폐암, 췌장암, 비소세포성폐암, 간암, 식도암, 소장암, 항문부근암, 나팔관암종, 자궁내막암종, 질암종, 음문암종, 호지킨병, 방광암, 신장암, 수뇨관암, 신장세포암종, 신장골반암종, 골암, 피부암, 두부암, 경부암, 피부흑색종, 안구내흑색종, 내분비선암, 갑상선암, 부갑상선암, 부신암, 연조직육종, 요도암, 음경암, 중추신경계(central nervous system; CNS) 종양, 1차 CNS 림프종, 척수종양, 뇌간신경교종, 뇌하수체선종 등이 있으며, 다발성 골수종(multiple myeloma)인 것이 바람직하다.In the present invention, the cancer is selected from the group consisting of multiple myeloma, colorectal cancer, breast cancer, cervical cancer, cervical cancer, ovarian cancer, prostate cancer, brain tumor, head and neck carcinoma, melanoma, myeloma, leukemia, lymphoma, gastric cancer, lung cancer, Ovarian cancer, kidney cancer, renal cell carcinoma, renal pelvic carcinoma, bone cancer, skin cancer, tofu, ovarian cancer, endometrial carcinoma, endometrial carcinoma, vulvar carcinoma, vulvar carcinoma, Cancer of the central nervous system (CNS), primary CNS lymphoma, spinal cord tumor, cervical cancer, endometrial carcinoma, thyroid cancer, pituitary adenocarcinoma, soft tissue sarcoma, Tumor, brainstem glioma, pituitary adenoma, and multiple myeloma are preferable.
본 발명의 일실시예에 있어서, 암의 예방 또는 치료는 암세포의 소포체(endoplasmic reticulum, ER) 스트레스로 인한 세포사멸에 의해 달성될 수 있다.In one embodiment of the present invention, the prevention or treatment of cancer can be accomplished by apoptosis due to endoplasmic reticulum (ER) stress.
본 발명의 일 실시예에서는 왕불류행 추출물 처리에 의한 다발성 골수종 세포의 사멸이 증가하는 것을 확인하였으며, 이와 같은 항암 활성 기작을 확인하기 위하여 세포사멸 관련 단백질들과 ER-스트레스 관련 세포사멸 유발 단백질들의 발현 변화를 확인한 결과, 왕불류행 추출물 처리에 의해 세포사멸 관련 Pro-PARP 및 procaspase-3이 감소하고 Bax 발현이 증가함을 확인함으로써 본 발명의 왕불류행 추출물이 ER-스트레스를 유발하고 이를 통해 세포사멸을 유도해 항암 활성을 나타내는 것임을 확인하였다.In one embodiment of the present invention, it was confirmed that the death of multiple myeloma cells by the treatment with the ascorbic acid extract was increased, and in order to confirm the anticancer activity mechanism, the expression of the apoptosis-related proteins and the ER- As a result of confirming the change, it was confirmed that the pro-PARP and procaspase-3 related to apoptosis were decreased and the expression of Bax was increased by the treatment with the extract of Wangwolyulgi, so that the extract of the present invention caused ER-stress, Induced anticancer activity.
본 발명에서의 용어, "apoptosis"는 세포자멸사라고도 하며, 일종의 계획된 세포 죽음(programmed cell death; PCD)으로서, 우리 몸 안에 입력되어 있는 생체 프로그램에 의해 비정상 세포, 손상된 세포, 노화된 세포가 스스로 자살해 사멸함으로써 전체적인 신체 건강을 유지하도록 하는 메커니즘이다. The term "apoptosis" in the present invention, also called apoptosis, is a kind of programmed cell death (PCD) in which abnormal cells, damaged cells, It is a mechanism to maintain overall physical health by decay.
본 발명의 왕불류행 추출물은 임상 투여시에 경구 및 비경구의 여러 가지 제형으로 투여될 수 있으며, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 제조된다.The extract of the present invention can be administered orally or parenterally in various dosage forms during clinical administration. In the case of formulation, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, .
경구투여를 위한 고형 제제에는 정제, 환자, 산제, 과립제, 캡슐제, 트로키제 등이 포함되며, 이러한 고형 제제는 하나 이상의 본 발명의 왕불류행 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘, 수크로스(sucrose), 락토오스(lactose) 또는 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구 투여를 위한 액상 제제로는 현탁제, 내용액제, 유제 또는 시럽제 등이 해당되는데, 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Solid formulations for oral administration include tablets, patients, powders, granules, capsules, troches and the like, which may contain one or more excipients such as starch, calcium carbonate Sucrose, lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions or syrups. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like are included in addition to commonly used simple diluents such as water and liquid paraffin. .
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁용제, 유제, 동결건조제제, 좌제 등이 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세롤, 젤라틴 등이 사용될 수 있다.Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, and the like. Examples of the non-aqueous solvent and suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As a base for suppositories, witepsol, macrogol, tween 61, cacao paper, laurin, glycerol, gelatin and the like can be used.
또한, 본 발명의 왕불류행 추출물의 인체에 대한 효과적인 투여량은 환자의 나이, 몸무게, 성별, 투여형태, 건강상태 및 질환 정도에 따라 달라질 수 있으며, 일반적으로 약 0.001-100 mg/kg/일이며, 바람직하게는 0.01-35 mg/kg/일이다. 몸무게가 70㎏인 성인 환자를 기준으로 할 때, 일반적으로 0.07-7000 mg/일이며, 바람직하게는 0.7-2500 ㎎/일이며, 의사 또는 약사의 판단에 따라 일정시간 간격으로 1일 1회 내지 수회로 분할 투여할 수도 있다.In addition, the effective dose of the extract according to the present invention on the human body may vary depending on the patient's age, weight, sex, dosage form, health condition and disease severity, and is generally about 0.001-100 mg / kg / day , Preferably 0.01 to 35 mg / kg / day. It is generally from 0.07 to 7000 mg / day, preferably from 0.7 to 2500 mg / day, based on an adult patient weighing 70 kg, and may be administered once a day It may be divided into several doses.
항암보조제 조성물Anticancer adjuvant composition
본 발명은 왕불류행 추출물을 유효성분으로 포함하는 항암보조제를 제공한다.The present invention provides an anticancer adjuvant comprising an extract of quercetin as an active ingredient.
본 발명의 용어, "항암보조제"는 항암제의 항암효과를 증대시키고, 항암제의 부작용을 억제하거나 개선시키 위하여 사용될 수 있으며, 항암제와 병용하여 환자에게 투여될 수 있다. The term "anticancer adjuvant" of the present invention can be used to increase the anticancer effect of an anticancer agent, to suppress or improve side effects of the anticancer agent, and to administer it to a patient in combination with an anticancer agent.
건강기능성식품 및 건강식품 조성물Health functional food and health food composition
본 발명의 왕불류행 추출물을 건강기능식품 및 건강식품으로 사용하는 경우, 식품의 종류에는 특별한 제한은 없다. 본 발명의 왕불류행 추출물을 첨가할 수 있는 식품의 예로는 드링크제, 육류, 소시지, 빵, 비스킷, 떡, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 알코올 음료 및 비타민 복합제, 유제품 및 유가공 제품 등이 있으며, 통상적인 의미에서의 건강기능식품 및 건강식품을 모두 포함한다.When the extract of the present invention is used as a health functional food and a health food, there is no particular limitation on the type of food. Examples of foods to which the extract of the present invention can be added include milk products such as drinks, meat, sausage, bread, biscuits, rice cakes, chocolate, candies, snacks, confectionery, pizza, ramen noodles, other noodles, gums, , Various soups, beverages, alcoholic beverages and vitamin complexes, dairy products and dairy products, and includes both health functional foods and health foods in a conventional sense.
본 발명에 따른 왕불류행 추출물을 함유하는 건강기능식품 및 건강식품 조성물은 식품에 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 왕불류행 추출물의 혼합량은 그의 사용 목적(예방 또는 개선용)에 따라 적합하게 결정될 수 있다. 일반적으로, 건강기능식품 및 건강식품 중의 상기 조성물의 양은 전체 식품 중량의 0.1 내지 90 중량부로 가할 수 있다. 그러나 건강 유지를 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 왕불류행 추출물은 상기 범위 이상의 양으로도 사용될 수 있다.The health functional food and health food composition containing the extract according to the present invention can be added directly to food or used together with other food or food ingredients and can be suitably used according to a conventional method. The mixing amount of the in-flight extract can suitably be determined according to its intended use (for prevention or improvement). Generally, the amount of the composition in the health functional food and the health food may be 0.1 to 90 parts by weight of the total food weight. However, in the case of long-term intake for the purpose of health maintenance or health control, the amount may be less than the above range, and there is no problem in terms of safety, so that the ascorbic acid extract can be used in an amount exceeding the above range.
본 발명의 건강기능식품 및 건강식품 조성물은 지시된 비율로 필수 성분으로서 본 발명 왕불류행 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트라이톨 등의 당알코올이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 건강기능식품 및 건강식품 조성물 100 당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.The health functional foods and health food compositions of the present invention are not particularly limited as long as they contain the extract of the present invention as an essential ingredient in the indicated ratios, and may contain various flavors or natural carbohydrates . Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above . The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 parts of the health functional food and health food composition of the present invention.
상기 외에 본 발명의 왕불류행 추출물을 함유하는 건강기능식품 및 건강식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 건강기능식품 및 건강식품 조성물은 천연 과일쥬스 및 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다.In addition to the above, the health functional food and the health food composition containing the extract of the present invention may be in the form of a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, Etc.), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks and the like. In addition, the health functional food and health food composition of the present invention may contain natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks.
이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 왕불류행 추출물을 함유하는 건강기능식품 및 건강식품 조성물 100 중량부 당 0.1 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.These components may be used independently or in combination. Although the ratio of such additives is not so important, it is generally selected in the range of 0.1 to about 20 parts by weight per 100 parts by weight of the health functional food and health food composition containing the ascorbic acid extract of the present invention.
이하, 본 발명을 하기의 실시예에 의하여 더욱 상세히 설명한다. 단, 하기의 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기의 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are illustrative of the present invention, and the present invention is not limited by the following examples.
<실시예 1> 왕불류행(Silene repens Patrin) 추출물 제조Example 1 Preparation of Silene repens Patrin Extract
왕불류행 추출물을 제조하기 위해, 100% 에탄올 1L에 왕불류행 1kg을 삼각 플라스크에 넣고 상온에서 96시간 추출한 뒤 거름종이로 약재를 걸러주어 왕불류행 에탄올 추출액을 제조하였다. 상기 왕불류행 에탄올 추출액을 100ml씩 50℃에서 3시간 동안 감압 농축한 후 -80℃에서 4~10Pa 압력으로 6시간동안 동결 건조 시킨 후 다시 -80℃에서 얼려 주고 다시 동결 건조를 시키는 작업을 3회 반복 하여 왕불류행 에탄올 추출물을 제조하였다. 이후 약 수저를 이용하여 동결 건조시킨 왕불류행 추출물을 긁어 낸 후 무게를 측정하여 수득률을 계산 한다. DMSO(dimethyl sulfoxide)1ml에 왕불류행 추출물을 200mg으로 녹여 200mg/ml의 농도로 Stock 을 만든 후 1.5ml 튜브에 넣어 -20℃에 보관 하였다.In order to prepare the extract of Wangbool, 1kg of 100% ethanol was added to the Erlenmeyer flask, and extracted for 96 hours at room temperature. 100 ml of the above-described ethanol extract of the above-mentioned double-stranded ethanol was concentrated under reduced pressure at 50 ° C for 3 hours, lyophilized at -80 ° C to 4-10 Pa pressure for 6 hours, frozen at -80 ° C again, The ethanol extracts were prepared by repeating the procedure. After that, the freeze-dried extract of the long-bodied larvae is scraped off by using a spoon, and then the weight is measured and the yield is calculated. DMSO (dimethyl sulfoxide) was dissolved in 200mg of the extract, and the stock was prepared at a concentration of 200mg / ml. The stock was stored at -20 ° C in a 1.5ml tube.
<실험예 1> 왕불류행 추출물의 다발성 골수종에 대한 세포 독성 확인<Experimental Example 1> Cytotoxicity test for multiple myeloma of Wolbryu extract
상기 실시예 1에서 제조한 왕불류행 추출물의 다발성 골수종에 대한 항암 활성을 확인하기 위하여, 다발성 골수종 세포주인 U937 세포주 (한국세포주은행)와 U266 세포주 (ATCC) 50㎕를 96웰-플레이트에 2×104 세포/웰이 되도록 분주한 뒤, 10% inactivated fetal bovine serum 및 1% penicillin-streptomycin을 첨가한 RPMI 배지에서, 37℃의 5% CO2 인큐베이터 (MCO-15AC, Sanyo, Osaka, Japan)로 배양하였다. To confirm the anticancer activity against the multiple myeloma of the hyperlipidemic extract prepared in Example 1, 50 쨉 l of U937 cell line (Korean Cell Line Bank) and U266 cell line (ATCC), which are multiple myeloma cell lines, 4 cells / well, and then in RPMI medium supplemented with 10% inactivated fetal bovine serum and 1% penicillin-streptomycin, And cultured in a 5% CO 2 incubator (MCO-15AC, Sanyo, Osaka, Japan) at 37 ° C.
배양한 세포주 U937와 U266에 상기 실시예 1에서 제조한 왕불류행 추출물을 0, 25, 50, 100 및 200㎍/ml의 농도로 각각 50㎕씩 처리한 뒤, 24시간 동안 인큐베이션하였다. 인큐베이션한 세포에 EZ-Cytox 시약 (DoGen)을 10㎕ 처리하고 30분 내지 4시간 동안 인큐베이션한 뒤, 마이크로플레이트 리더기 (Bio-rad Model 680)를 이용하여 흡광도 450nm 파장대에서 세포 생존율을 확인하였다. 도 1a 및 도 1b에 왕불류행 추출물 처리에 의한 다발성 골수종 세포주 U937과 U266의 세포 생존율 결과를 나타내었다.Each of the cultured cell lines U937 and U266 was treated with 50 μl of each of the extracts prepared in Example 1 at concentrations of 0, 25, 50, 100 and 200 μg / ml, respectively, followed by incubation for 24 hours. The incubated cells were treated with 10 E of EZ-Cytox reagent (DoGen) and incubated for 30 minutes to 4 hours. Cell viability was confirmed at a wavelength of 450 nm using a microplate reader (Bio-rad Model 680). FIGS. 1A and 1B show the cell survival rates of the multiple myeloma cell lines U937 and U266, respectively, by treatment with the extract of Wangwu.
상기 도 1a 및 도 1b에 나타낸 바와 같이, 왕불류행 추출물의 농도의존적으로 다발성 골수종에 독성을 나타냈고, 100㎍/ml 이후부터는 농도에 큰 차이 없이 다발성 골수종을 사멸시키는 것을 알 수 있었다.As shown in FIG. 1A and FIG. 1B, it was found that the extracts of the present invention were toxic to multiple myeloma in a concentration-dependent manner, and the multiple myeloma was killed at a concentration of 100 μg / ml or less.
<실험예 2> 왕불류행 추출물에 의한 다발성 골수종의 세포사멸 및 소포체스트레스 유발 효과 확인 <Experimental Example 2> Determination of apoptosis and endothelial stress-inducing effect of multiple myeloma using the extract
상기 실시예 1에서 제조한 왕불류행 추출물이 다발성 골수종에서의 세포사멸에 미치는 영향을 확인하기 위해, 세포사멸 진행시 절단되는 것으로 알려진 PARP(Poly ADP ribose polymerase)와 DNA 손상을 유도하고 ER 스트레스를 유발하여 세포사멸의 마커로 이용되는 CHOP(C/EBP homologous protein)의 발현 정도를 웨스턴 블롯 분석으로 확인하였다. In order to examine the effect of the extract of the present invention on cell death in multiple myeloma, PARP (Poly ADP ribose polymerase), which is known to be cleaved at the time of cell death, induces DNA damage and induces ER stress The expression level of CHOP (C / EBP homologous protein) used as a marker of apoptosis was confirmed by Western blot analysis.
다발성 골수종 세포주인 U937와 U266 세포주에 상기 실시예 1에서 제조한 왕불류행 추출물을 0, 20 및 40㎍/ml로 각각 처리하고 24시간 동안 37℃의 5% CO2 인큐베이터로 인큐베이션 하였다. 그 후, 세포를 수집하여 PBS로 워싱하고, 세포 파쇄 버퍼 RIPA (20mM Tris-HCL (pH 7.5), 150mM NaCl, 1mM NaEDTA, 1mM EGTA, 1% NP-40, 1% sodium pyrophophate, 1mM beta-glycerophosphate, 1mM Na3VO4 및 1㎍/ml leupeptin (Cell signaling))를 첨가하여 30분간 4℃에서 세포파쇄하였다. 세포파쇄물을 15,520×g에서 20분간 원심 분리하여 세포막 성분 등을 제거한 후, RC DC™ Protein Assay Kit II(protein assay kit) (Bio-rad, USA)를 사용하여 단백질을 정량하여 시료별 (왕불류행 추출물 0, 20 및 40㎍/ml 처리군들)로 동일한 단백질의 양이 포함되도록 조절하였다. 준비된 단백질 시료에 5×로딩 다이를 넣고 5분 동안 95℃로 가열하여 단백질을 변성시켰다. 그 후, 8~10% SDS-PAGE 젤에 시료를 로딩하여 90 내지 100V로 1시간 30분 내지 3시간 동안 전기영동을 수행하였으며, 젤 위에서 분리된 단백질들을 200mA~300mA로 1시간 내지 2시간 동안 멤브레인으로 트랜스퍼하였다. 단백질이 트랜스퍼된 멤브레인을 5% 스킴 밀크가 포함된 TBST (tris buffered saline, pH 7.5) 용액으로 상온에서 1시간 동안 블로킹한 뒤 1차 항체 항-PARP및 항-CHOP 를 각각 1:500으로 희석하여 블로킹한 멤브레인과 4℃에서 오버나잇으로 반응시켰다. 멤브레인을 TBST로 3회 워싱한 뒤 horseradish peroxidase가 결합된 항-rabbit IgG를 1:1,000으로 희석하여 상온에서 멤브레인과 2시간 동안 반응시킨 다음 TBST로 3회 워싱하였다. 워싱한 멤브레인을 chemiluminescent reagent와 1 내지 3분 동안 반응시키고 필름에 감광하여 단백질 밴드를 가시화하였다. 도 2a 및 도 2b에 왕불류행 추출물 처리에 의한 다발성 골수종 세포주 U937과 U266의 세포사멸 관련 단백질과 ER스트레스 유발 관련 단백질의 발현 정도를 확인하였다.The U937 and U266 cell lines, which are multiple myeloma cell lines, were treated with 0, 20 and 40 / / ml of the extract from the above-described Example 1, respectively, and incubated in a 5% CO 2 incubator at 37 캜 for 24 hours. Cells were then harvested, washed with PBS and resuspended in cell-disruption buffer RIPA (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM NaEDTA, 1 mM EGTA, 1% NP-40, 1% sodium pyrophophate, 1 mM beta-glycerophosphate , 1 mM Na 3 VO 4 and 1 [mu] g / ml leupeptin (Cell signaling)) was added thereto and the cells were disrupted at 4 [deg.] C for 30 minutes. Cell lysates were centrifuged at 15,520 × g for 20 minutes to remove cell membrane components and the proteins were quantified using RC DC ™ Protein Assay Kit II (Bio-Rad, USA) Extracts 0, 20 and 40 [mu] g / ml treated groups). Proteins were denatured by adding 5x loading dies to the prepared protein samples and heating to 95 ° C for 5 minutes. Thereafter, the sample was loaded on an 8-10% SDS-PAGE gel and electrophoresed at 90-100 V for 1 hour and 30 minutes to 3 hours. Proteins separated from the gel were incubated at 200 mA to 300 mA for 1 hour to 2 hours And transferred to the membrane. Protein-transferred membranes were blocked with TBST (tris buffered saline, pH 7.5) solution containing 5% skim milk for 1 hour at room temperature, followed by dilution of primary antibody anti-PARP and anti-CHOP to 1: 500 The membrane was reacted with the blocked membrane overnight at 4 ° C. The membranes were washed three times with TBST, and anti-rabbit IgG conjugated with horseradish peroxidase was diluted to 1: 1,000, reacted with the membrane at room temperature for 2 hours, and then washed three times with TBST. The washed membrane was reacted with a chemiluminescent reagent for 1 to 3 minutes and exposed to a film to visualize the protein band. FIG. 2A and FIG. 2B show the expression levels of the apoptosis-related proteins and the ER stress-related proteins of the multiple myeloma cell lines U937 and U266, respectively, by treatment with the ascorbic acid extract.
상기 도 2a 및 도 2b에 나타낸 바와 같이, 왕불류행 추출물의 농도에 의존적으로 PARP의 절단이 증가하고, CHOP의 발현이 증가하여 세포사멸과 ER-스트레스가 왕불류행 추출물에 의해 향상되는 것을 알 수 있어, 왕불류행 추출물이 다발성 골수종의 세포 사멸을 농도 의존적으로 유발하는 것을 알 수 있었다.As shown in FIGS. 2A and 2B, it can be seen that the cleavage of PARP is increased and the expression of CHOP is increased depending on the concentration of the quinquerring extract, and the cell death and the ER-stress are improved by the quinquerring extract , And the extracts of Wangwolyong were found to induce apoptosis in multiple myeloma cells in a concentration-dependent manner.
<실험예 3> 다발성 골수종에서의 왕불류행 추출물의 활성산소 유발에 따른 세포사멸 효과 확인<Experimental Example 3> Determination of apoptotic effect according to the induction of reactive oxygen species
상기 실시예 1에서 제조한 왕불류행 추출물이 다발성 골수종에 미치는 영향을 확인하기 위하여, 다발성 골수종 세포주인 U937 세포주와 U266 세포주 50㎕를 96웰-플레이트에 2×104 세포/웰이 되도록 분주한 뒤, ROS 억제제인 NAC (N-Acetyl-L-cysteine)를 5mM 농도로 1시간 전처리 후 상기 실시예 1에서 제조한 왕불류행 추출물 50㎕을 40㎍/ml농도로 처리한 뒤, 24시간 동안 인큐베이션 하였다. 인큐베이션 한 세포에 EZ-Cytox 시약 (DoGen)을 10㎕ 처리하고 30분 내지 4시간 동안 인큐베이션한 뒤, 마이크로플레이트 리더기 (Bio-rad Model 680)를 이용하여 흡광도 450nm 파장대에서 세포 생존율을 확인하였다. 도 3a 및 도 3b에 왕불류행 추출물 처리에 의한 다발성 골수종 세포주 U937과 U266에서의 활성산소 생성과 세포 독성 사이 상관 관계를 확인하였다.In order to examine the effect of the extract on the hyperlipidemia produced in Example 1 on multiple myeloma, U937 cell line and 50 μl U266 cell line, which are multiple myeloma cell lines, were divided into 96 well-plates at 2 × 10 4 cells / well , NAC (N-Acetyl-L-cysteine), which is an ROS inhibitor, was pretreated at a concentration of 5 mM for 1 hour, treated with 50 왕 of the umbellate-like extract prepared in Example 1 at a concentration of 40 / / ml and then incubated for 24 hours . The incubated cells were treated with 10 E of EZ-Cytox reagent (DoGen) and incubated for 30 minutes to 4 hours. Cell viability was confirmed at a wavelength of 450 nm using a microplate reader (Bio-rad Model 680). 3A and 3B, the correlation between the production of active oxygen and the cytotoxicity of U937 and U266 in the multiple myeloma cell lines by the treatment with the ascorbic acid extract was confirmed.
상기 도 3a 및 도 3b에 나타낸 바와 같이, 왕불류행을 40㎍/ml 처리시 세포 생존율이 감소된 반면, ROS 억제제인 NAC 처리시 세포 생존율이 증가 된 것을 확인 할 수 있었다. 따라서, 왕불류행은 활성산소를 증가시킴으로써 세포사멸을 유도 한다는 것을 알 수 있었다.As shown in FIGS. 3A and 3B, it was confirmed that the cell viability was decreased when treating the quadriceps with 40 μg / ml, while the cell viability was increased when treated with NAC, an ROS inhibitor. Therefore, it can be seen that the quadriceps induce apoptosis by increasing reactive oxygen species.
이제까지 본 발명에 대하여 그 바람직한 실시예들을 중심으로 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 변형된 형태로 구현될 수 있음을 이해할 수 있을 것이다. 그러므로 개시된 실시예들은 한정적인 관점이 아니라 설명적인 관점에서 고려되어야 한다. 본 발명의 범위는 전술한 설명이 아니라 특히 청구범위에 나타나 있으며, 그와 동등한 범위내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.The present invention has been described with reference to the preferred embodiments. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the present invention is indicated by the appended claims rather than by the foregoing description, and all differences within the scope of equivalents thereof should be construed as being included in the present invention.
Claims (11)
A pharmaceutical composition for preventing or treating cancer comprising an extract of Silene repens Patrin as an active ingredient.
상기 추출물은 물, 탄소수 1 내지 4의 알코올 또는 이들의 혼합 용매로 추출한 것을 특징으로 하는 조성물.
The method according to claim 1,
Wherein the extract is extracted with water, an alcohol having 1 to 4 carbon atoms or a mixed solvent thereof.
상기 추출물은 탄소수 1 내지 4의 알코올로 추출한 것을 특징으로 하는 조성물.
3. The method of claim 2,
Wherein the extract is extracted with an alcohol having 1 to 4 carbon atoms.
상기 추출물은 에탄올로 추출한 것을 특징으로 하는 조성물.
The method of claim 3,
Wherein the extract is extracted with ethanol.
상기 추출물은 암세포의 소포체(endoplasmic reticulum, ER) 스트레스로 인한 세포사멸을 유도하는 것을 특징으로 하는 조성물.
The method according to claim 1,
Wherein said extract induces apoptosis due to endoplasmic reticulum (ER) stress of cancer cells.
상기 추출물은 활성 산소(reactive oxygen species, ROS)의 생성량을 증가시키는 것을 특징으로 하는 조성물.
The method according to claim 1,
Wherein the extract increases the amount of reactive oxygen species (ROS) produced.
상기 암은 다발성 골수종, 대장암, 유방암, 자궁암, 자궁경부암, 난소암, 전립선암, 뇌종양, 두경부암종, 흑색종, 골수종, 백혈병, 림프종, 위암, 폐암, 췌장암, 비소세포성폐암, 간암, 식도암, 소장암, 항문부근암, 나팔관암종, 자궁내막암종, 질암종, 음문암종, 호지킨병, 방광암, 신장암, 수뇨관암, 신장세포암종, 신장골반암종, 골암, 피부암, 두부암, 경부암, 피부흑색종, 안구내흑색종, 내분비선암, 갑상선암, 부갑상선암, 부신암, 연조직육종, 요도암, 음경암, 중추신경계(central nervous system; CNS) 종양, 1차 CNS 림프종, 척수종양, 뇌간신경교종 및 뇌하수체선종으로 이루어진 그룹에서 선택되는 어느 하나인 것을 특징으로 하는 조성물.
The method according to claim 1,
Wherein the cancer is selected from the group consisting of multiple myeloma, colorectal cancer, breast cancer, uterine cancer, cervical cancer, ovarian cancer, prostate cancer, brain tumor, head and neck carcinoma, melanoma, myeloma, leukemia, lymphoma, gastric cancer, pancreatic cancer, Renal cancer, renal cell carcinoma, renal pelvic carcinoma, bone cancer, skin cancer, head cancer, head and neck cancer, endometrial carcinoma, endometrial carcinoma, endometrial carcinoma, vulvar carcinoma, Hodgkin's disease, bladder cancer, Cancer of the central nervous system (CNS), primary CNS lymphoma, spinal cord tumor, brainstem neuron, neuroendocrine carcinoma, soft tissue sarcoma, urothelial carcinoma, Glioma, and pituitary adenoma. ≪ RTI ID = 0.0 > 21. < / RTI >
상기 암은 다발성 골수종(multiple myeloma)인 암의 예방 또는 치료용 약학적 조성물.
The method according to claim 1,
Wherein said cancer is a multiple myeloma.
An anti-cancer adjuvant composition comprising Silene repens Patrin extract.
A health functional food composition for preventing or ameliorating cancer, which comprises extract of Silene repens Patrin .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170147826A KR102050639B1 (en) | 2017-11-08 | 2017-11-08 | Composition for preventing and treating a cancer comprising Silene repens Patrin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170147826A KR102050639B1 (en) | 2017-11-08 | 2017-11-08 | Composition for preventing and treating a cancer comprising Silene repens Patrin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190066637A true KR20190066637A (en) | 2019-06-14 |
| KR102050639B1 KR102050639B1 (en) | 2019-11-29 |
Family
ID=66846481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170147826A KR102050639B1 (en) | 2017-11-08 | 2017-11-08 | Composition for preventing and treating a cancer comprising Silene repens Patrin |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102050639B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024090952A1 (en) * | 2022-10-27 | 2024-05-02 | 경희대학교 산학협력단 | Composition for preventing or treating radiation-resistant head and neck cancer, comprising melandrium herb extract as active ingredient |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102247107B1 (en) * | 2019-10-14 | 2021-05-03 | 경희대학교 산학협력단 | Composition for preventing and treating bone diseases comprising melandrii herba |
| KR20220057865A (en) | 2020-10-30 | 2022-05-09 | 경희대학교 산학협력단 | Composition for preventing and treating a pancreatic cancer comprising extracts of Sappan Lignum |
| KR102450560B1 (en) | 2020-10-30 | 2022-10-04 | 경희대학교 산학협력단 | Composition for preventing and treating a blood cancer comprising extracts of Draconis sanguis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120109139A (en) * | 2011-03-28 | 2012-10-08 | 주식회사한국전통의학연구소 | Composition for treatment of lung cancer and functional food comprising extract of melandrii herba |
| KR20150070303A (en) | 2012-10-17 | 2015-06-24 | 자피오텍 게엠베하 | Anthocyanidin complex for the treatment of multiple myeloma |
-
2017
- 2017-11-08 KR KR1020170147826A patent/KR102050639B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120109139A (en) * | 2011-03-28 | 2012-10-08 | 주식회사한국전통의학연구소 | Composition for treatment of lung cancer and functional food comprising extract of melandrii herba |
| KR20150070303A (en) | 2012-10-17 | 2015-06-24 | 자피오텍 게엠베하 | Anthocyanidin complex for the treatment of multiple myeloma |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024090952A1 (en) * | 2022-10-27 | 2024-05-02 | 경희대학교 산학협력단 | Composition for preventing or treating radiation-resistant head and neck cancer, comprising melandrium herb extract as active ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102050639B1 (en) | 2019-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102050639B1 (en) | Composition for preventing and treating a cancer comprising Silene repens Patrin | |
| KR101715274B1 (en) | Composition containing extract or fractions of Chrysanthemum indicum L. for treating, improving or preventing inflammatory disease | |
| KR101734979B1 (en) | Composition for preventing and treating cancer, and enhancing the immune action | |
| KR101787008B1 (en) | A composition comprising the combination of flavonoid derivatives and iridoid derivatives for treating and preventing Male Infertility | |
| KR101982937B1 (en) | Composition for preventing and treating a cancer comprising Cnidium officinale Makion | |
| KR101152479B1 (en) | Composition comprising defatted green tea seed extract for preventing and treating inflammatory or cancer disease | |
| KR101188581B1 (en) | Composition comprising Cyperus rotundus methalnol extracts for preventing or treating Sepsis | |
| KR102113140B1 (en) | Composition for treatment or prevention of cancer comprising extract of Salvia miltiorrhiza and Prunus persica Batsch | |
| KR102279105B1 (en) | Composition for preventing or treating renal disease comprising Zizyphus jujuba MILL extract | |
| KR20180137918A (en) | Composition for preventing and treating a cancer comprising curcuma zedoaria | |
| KR101941368B1 (en) | Composition for preventing or treating cancer comprising Salvia militiorrhiza | |
| KR20040033983A (en) | Composition comprising the stem bark extract of Acanthopanax senticosus and liriodendrin therefrom having anti-inflammatory and antinociceptive activity | |
| KR100629624B1 (en) | Composition comprising the leaf extract of Rubus Coreanus having anti-inflammatory activity | |
| KR20190051193A (en) | Composition for preventing and treating a cancer comprising Rhus verniciflua Strokes | |
| KR102144264B1 (en) | Composition for preventing and treating a cancer comprising leonurus sibiricus | |
| KR102450560B1 (en) | Composition for preventing and treating a blood cancer comprising extracts of Draconis sanguis | |
| KR20190054852A (en) | Pharmaceutical composition for anti-inflammatory Ethanol Extract of Antirrhinum majus as an active ingradient | |
| KR20190111199A (en) | Composition for preventing, ameliorating or treating anti-cancer drug-resistant lung cancer comprising gliotoxin as effective component | |
| KR102214014B1 (en) | Antioxidant or anticancer composition comprising extract of Osmanthus heterophylla leaf | |
| KR102197296B1 (en) | Pharmaceutical composition for preventing or treating lung cancer comprising extract of Schoenoplectus triqueter | |
| KR101926021B1 (en) | Pharmaceutical composition comprising extract of Telectadium dongnaiense for preventing or treating colon cancer | |
| KR20190000031A (en) | Composition for preventing and treating a cancer comprising carthamus tinctorius | |
| KR102455428B1 (en) | Medical composition for preventing or treating cancer and health functional food | |
| KR20210112534A (en) | Skin cancer prevention or skin cancer metastasis inhibiting composition comprising Inula japonica Thunberg extract | |
| KR101457969B1 (en) | Pharmaceutical composition comprising leaf extract of Abutilon theophrasti Medicus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| X091 | Application refused [patent] | ||
| AMND | Amendment | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |